Pertussis in India: Past, Present, and Future.


Journal

Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442

Informations de publication

Date de publication:
04 2023
Historique:
received: 12 05 2022
accepted: 18 08 2022
revised: 04 08 2022
pubmed: 16 12 2022
medline: 21 3 2023
entrez: 15 12 2022
Statut: ppublish

Résumé

While vaccines have markedly reduced the incidence of pertussis, a resurgence has occurred in many countries. Until recently, pertussis has not been recognized as an important public health challenge in India due to its successful infant immunization program. However, India still accounts for a large proportion of the world's cases, and increasing reports of pertussis in other countries and in neonates have regenerated interest in pertussis among Indian authorities. The Global Pertussis Initiative (GPI) Annual Meeting was held virtually in October 2020, in part, to gain a better understanding of the epidemiology and disease burden of pertussis and to explore opportunities to improve its prevention in India. There was a consensus that pertussis cases are being underestimated in India due to multiple factors, such as a reliance on passive surveillance and diagnostic challenges. India offers both whole-cell pertussis and acellular pertussis vaccines, but vaccine coverage is inconsistent across regions due to differences in vaccine availability, access to health care, and regional administrative challenges. This report summarizes the outcomes and considers the key clinical implications of this meeting. The GPI agreed that active surveillance of pertussis in India would be optimal and recommended several studies, including serosurveillance among women of reproductive age to assess the prevalence of recent pertussis infection and to enable policy changes that will enhance the rational use of acellular and whole-cell vaccines. It also recommended engagement with nongovernmental organizations in order to encourage pregnancy immunization in the public sector. To achieve effective control of pertussis in the future, the GPI recognizes there are opportunities to characterize the burden of pertussis in India appropriately and increase vaccination coverage in multiple age groups.

Identifiants

pubmed: 36522518
doi: 10.1007/s12098-022-04384-w
pii: 10.1007/s12098-022-04384-w
doi:

Substances chimiques

Pertussis Vaccine 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-399

Informations de copyright

© 2022. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.

Références

Esposito S, Stefanelli P, Fry NK, et al. World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG). Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines. Front Immunol. 2019;10:1344.
doi: 10.3389/fimmu.2019.01344 pubmed: 31333640 pmcid: 6616129
Adams DA, Gallagher KM, Jajosky RA, et al, Division of Notifiable Diseases and Healthcare Information. Office of Surveillance, Epidemiology, and Laboratory Services, CDC. Summary of notifiable diseases ̶ United States, 2011. MMWR Morb Mortal Wkly Rep. 2013;60:1–117.
pubmed: 23820934
Centers for Disease Control and Prevention (CDC). Jajosky RA, Hall PA, Adams DA, et al. Summary of notifiable diseases ̶ United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;53:1–79.
McIntyre P, Gidding H, Gilmour R, et al; National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell Q Rep. 2002;Suppl:i-xi, 1–111.
Chasaide CN, Mills KHG. Next-generation pertussis vaccines based on the induction of protective T cells in the respiratory tract. Vaccines (Basel). 2020;8:621.
doi: 10.3390/vaccines8040621 pubmed: 33096737
Wilk MM, Misiak A, McManus RM, Allen AC, Lynch MA, Mills KHG. Lung CD4 tissue-resident memory T cells mediate adaptive immunity induced by previous infection of mice with Bordetella pertussis. J Immunol. 2017;199:233–43.
doi: 10.4049/jimmunol.1602051 pubmed: 28533445
Bancroft T, Dillon MB, da Silva Antunes R, et al. Th1 versus Th2 T cell polarization by wholecell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. Cell Immunol. 2016;304–305:35–43.
doi: 10.1016/j.cellimm.2016.05.002 pubmed: 27212461 pmcid: 4899275
Brummelman J, Wilk MM, Han WG, van Els CA, Mills KH. Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis. 2015;73:ftv067.
doi: 10.1093/femspd/ftv067 pubmed: 26347400 pmcid: 4626578
Chitkara AJ, Pujadas Ferrer M, Forsyth K, et al. Pertussis vaccination in mixed markets: recommendations from the Global Pertussis Initiative. Int J Infect Dis. 2020;96:482–8.
doi: 10.1016/j.ijid.2020.04.081 pubmed: 32413606
Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. mBio. 2014;5:e01074.
doi: 10.1128/mBio.01074-14 pubmed: 24757216 pmcid: 3994516
Bell CA, Russell ML, Drews SJ, et al. Acellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010–2015, a Canadian Immunization Research Network (CIRN) study. Vaccine. 2019;37:4140–6.
doi: 10.1016/j.vaccine.2019.05.067 pubmed: 31164304
Burdin N, Handy LK, Plotkin SA. What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis vaccines. Cold Spring Harb Perspect Biol. 2017;9:a029454.
doi: 10.1101/cshperspect.a029454 pubmed: 28289064 pmcid: 5710106
Damron FH, Barbier M, Dubey P, et al. Overcoming waning immunity in pertussis vaccines: workshop of the National Institute of Allergy and Infectious Diseases. J Immunol. 2020;205:877–82.
doi: 10.4049/jimmunol.2000676 pubmed: 32769142
Klein NP, Bartlett J, Fireman B, et al. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine. 2017;35:3395–400.
doi: 10.1016/j.vaccine.2017.05.008 pubmed: 28506516
Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-deficient Bordetella pertussis, vaccine driven evolution, and reemergence of pertussis. Emerg Infect Dis. 2021;27:1561–6.
doi: 10.3201/eid2706.203850 pubmed: 34014152 pmcid: 8153889
Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131:e1047–52.
doi: 10.1542/peds.2012-1928 pubmed: 23478868
Forsyth KD, Tan T, von König CW, Heininger U, Chitkara AJ, Plotkin S. Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update. Vaccine. 2018;36:7270–5.
doi: 10.1016/j.vaccine.2018.10.028 pubmed: 30337176
Bettampadi D, Lepkowski JM, Sen A, Power LE, Boulton ML. Vaccination inequality in India, 2002–2013. Am J Prev Med. 2021;60(1 Suppl 1):65–76.
doi: 10.1016/j.amepre.2020.06.034
World Health Organization. The Global Health Observatory. Indicators. Available at: https://www.who.int/data/gho/data/indicators . Accessed on 9 Nov 2022.
World Health Organization. The Global Health Observatory. Vaccine preventable diseases. Available at: https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/gho-immunization-vaccine-preventable-communicable-diseases . Accessed on 8 Nov 2022.
Agrawal A, Singh S, Kolhapure S, Kandeil W, Pai R, Singhal T. Neonatal pertussis, an underrecognized health burden and rationale for maternal immunization: a systematic review of South and South-East Asian countries. Infect Dis Ther. 2019;8:139–53.
doi: 10.1007/s40121-019-0245-2 pubmed: 31054089 pmcid: 6522626
S LJ, Basker MM, Verghese VP, et al. A seroepidemiological survey for pertussis among adolescents. Indian J Pediatr. 2021;88:509.
doi: 10.1007/s12098-021-03696-7 pubmed: 33594619
Ngilneii C. Whooping cough ̶ prevalence & deaths in India. Medindia. 2017. Available at: https://www.medindia.net/health_statistics/diseases/whooping-cough-india-health-statistics.asp . Accessed on 7 July 2021.
National Health Portal, India. Universal immunisation programme. Available at: https://www.nhp.gov.in/universal-immunisation-programme_pg . Accessed on 12 July 2021.
World Health Organization. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage, India, Administrative coverage. Available at: https://immunizationdata.who.int/pages/coverage/dtp.html?CODE=IND&ANTIGEN=&YEAR= . Accessed on 9 Nov 2022.
World Health Organization. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage, India, WHO/UNICEF Estimates of National Immunization Coverage. Available at: https://immunizationdata.who.int/pages/coverage/dtp.html?CODE=IND&ANTIGEN=&YEAR= . Accessed on 9 Nov 2022.
World Health Organization South-East Asia. Factsheet 2020: India. Expanded Programme on Immunization. Available at: https://apps.who.int/iris/bitstream/handle/10665/336757/ind-epi-factsheet-2020-eng.pdf?sequence=1&isAllowed=y . Accessed on 14 Sept 2021.
Dewan P, Shah D. Pertussis: 100-day disease over 50 years! Indian Pediatr. 2019;56:865–7.
doi: 10.1007/s13312-019-1613-4 pubmed: 31724542
Kasi SG, Shivananda S, Marathe S, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2020-21) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2021;58:44–53.
doi: 10.1007/s13312-021-2096-7 pubmed: 33257602
Puliyel J, Kaur J, Puliyel A, Sreenivas V. Deaths reported after pentavalent vaccine compared with death reported after diphtheria-tetanus-pertussis vaccine: an exploratory analysis. Med J DY Patil Vidyapeeth. 2018;11:99–105.
Lee AD, Cassiday PK, Pawloski LC, et al; Clinical Validation Study Group. Clinical evaluation and validation of laboratory methods for the diagnosis of Bordetella pertussis infection: Culture, polymerase chain reaction (PCR) and anti-pertussis toxin IgG serology (IgGPT). PLoS One. 2018;13:e0195979.
doi: 10.1097/INF.0000000000001767 pubmed: 29189613
Heininger U. Is there a need for a stand-alone acellular pertussis vaccine? Pediatr Infect Dis J. 2018;37:359–60.
doi: 10.1371/journal.pone.0195979 pubmed: 29652945 pmcid: 5898745

Auteurs

A J Chitkara (AJ)

Department of Pediatrics, Max Super Specialty Hospital, Shalimar Bagh, 118, Vaishali, Pitampura, Delhi, 110088, India. drajchitkara@outlook.com.

S Balasubramanian (S)

Department of Pediatrics, Kanchi Kamkoti CHILDS Trust Hospital, Chennai, Tamil Nadu, India.

Jaydeep Choudhury (J)

Department of Pediatrics, Institute of Child Health, Kolkata, India.

Nabaneeta Dash (N)

Department of Pediatrics, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.

Kevin Forsyth (K)

Department of Pediatrics, Flinders University, Adelaide, Australia.

Ulrich Heininger (U)

Department of Pediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland.

Daniela Flavia Hozbor (DF)

Department of Biological Sciences, Laboratorio VacSal. Instituto de Biotecnología y Biología Molecular, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CONICET, La Plata, Argentina.

Rudzani Muloiwa (R)

Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa.

Tina Tan (T)

Division of Infectious Diseases, Feinberg School of Medicine of Northwestern University, Chicago, IL, USA.

Carl Heinz Wirsing von König (CHW)

Independent Consultant, Krefeld, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH